Drug Profile
Trastuzumab biosimilar - Zydus
Alternative Names: VivitraLatest Information Update: 07 Jun 2023
Price :
$50
*
At a glance
- Originator Zydus Cadila
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Breast cancer